

Tsutomu Hirano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8071206/publications.pdf>

Version: 2024-02-01

109
papers

4,269
citations

87723

38
h-index

128067

60
g-index

111
all docs

111
docs citations

111
times ranked

4314
citing authors

#	ARTICLE	IF	CITATIONS
1	Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 3-14.	0.9	5
2	Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 762-774.	0.9	11
3	Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort. <i>Journal of Diabetes Investigation</i> , 2022, 13, 657-667.	1.1	18
4	Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway. <i>Biomedicines</i> , 2021, 9, 832.	1.4	7
5	A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4811.	1.8	20
6	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease—A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1509.	1.8	29
7	Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments. <i>Heart and Vessels</i> , 2020, 35, 1012-1024.	0.5	17
8	δ -Endorphin Mediates the Development and Instability of Atherosclerotic Plaques. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-11.	0.6	8
9	Legumain Promotes Atherosclerotic Vascular Remodeling. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2195.	1.8	18
10	Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E895-E907.	1.8	17
11	Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. <i>Diabetes Therapy</i> , 2019, 10, 215-228.	1.2	16
12	Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis. <i>Clinical Science</i> , 2019, 133, 1779-1796.	1.8	29
13	Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice. <i>Endocrine Connections</i> , 2019, 8, 536-546.	0.8	6
14	Involvement of Vascular Endothelial Cells in the Anti-atherogenic Effects of Liraglutide in Diabetic Apolipoprotein E-null Mice. <i>The Showa University Journal of Medical Sciences</i> , 2019, 31, 115-124.	0.1	0
15	Novel phytopeptide osmotin mimics preventive effects of adiponectin on vascular inflammation and atherosclerosis. <i>Metabolism: Clinical and Experimental</i> , 2018, 83, 128-138.	1.5	30
16	Neopterin Counters Vascular Inflammation and Atherosclerosis. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	38
17	Catestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injury-Induced Neointimal Hyperplasia. <i>Thrombosis and Haemostasis</i> , 2018, 118, 182-194.	1.8	58
18	Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 339-346.	1.1	10

#	ARTICLE	IF	CITATIONS
19	Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 223-229.	1.0	25
20	A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-9.	0.6	9
21	Inhibitory effects of vasostatin-1 against atherogenesis. <i>Clinical Science</i> , 2018, 132, 2493-2507.	1.8	19
22	Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/Macrophage Responses and Hyperlipidemic Mouse Plaque Phenotype. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1732.	1.8	26
23	Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1293.	1.8	63
24	Pathophysiology of Diabetic Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 771-782.	0.9	271
25	Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice. <i>Endocrinology</i> , 2018, 159, 2717-2732.	1.4	21
26	Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. <i>Cardiovascular Diabetology</i> , 2017, 16, 8.	2.7	119
27	Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	27
28	Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. <i>Lipids in Health and Disease</i> , 2017, 16, 21.	1.2	34
29	The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. <i>Cardiovascular Diabetology</i> , 2017, 16, 122.	2.7	39
30	Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice. <i>International Journal of Endocrinology</i> , 2017, 2017, 1-9.	0.6	9
31	Protective Effect of Anti-diabetic Drugs on Cardiovascular Diseases. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 1029-1036.	0.0	0
32	A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 441-454.	0.9	27
33	SP617OXIDIZED HDL INFLUENCES PREDICTIVE ABILITY OF APOLIPOPROTEIN A2 TO CVD EVENTS IN HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i301-i301.	0.4	0
34	Atheroprotective Effects of Tumor Necrosis Factor- α Stimulated Gene-6. <i>JACC Basic To Translational Science</i> , 2016, 1, 494-509.	1.9	27
35	Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 893-903.	1.5	30
36	Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and dipeptidyl peptidase-4 inhibitors in experimental animals. <i>Journal of Diabetes Investigation</i> , 2016, 7, 80-86.	1.1	44

#	ARTICLE	IF	CITATIONS
37	High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 81-94.	0.9	29
38	A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. <i>Diabetology International</i> , 2016, 7, 425-431.	0.7	1
39	Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association. <i>Lipids in Health and Disease</i> , 2016, 15, 57.	1.2	9
40	Counteractive effects of omentin-1 against atherogenesis. <i>Cardiovascular Research</i> , 2016, 110, 118-128.	1.8	113
41	Increased detection of mild cognitive impairment with type 2 diabetes mellitus using the Japanese version of the Montreal Cognitive Assessment: A pilot study. <i>Neurology and Clinical Neuroscience</i> , 2015, 3, 89-93.	0.2	7
42	A new device for foot sensory examination employing auto-presentation of shear force stimuli against the skin. <i>Journal of Biomechanical Science and Engineering</i> , 2015, 10, 14-00487-14-00487.	0.1	16
43	Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. <i>PLoS ONE</i> , 2015, 10, e0138332.	1.1	21
44	Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. <i>PLoS ONE</i> , 2015, 10, e0143396.	1.1	76
45	Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes. <i>Drugs in R and D</i> , 2015, 15, 245-251.	1.1	9
46	Vasoprotective Effects of Urocortin 1 against Atherosclerosis In Vitro and In Vivo. <i>PLoS ONE</i> , 2014, 9, e110866.	1.1	21
47	Elevated Small Dense Low-Density Lipoprotein Cholesterol as a Predictor for Future Cardiovascular Events in Patients with Stable Coronary Artery Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 755-767.	0.9	68
48	A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. <i>Peptides</i> , 2014, 54, 19-26.	1.2	97
49	Abnormal lipoprotein metabolism in diabetic nephropathy. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 206-209.	0.7	44
50	Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol. <i>Clinica Chimica Acta</i> , 2014, 427, 86-93.	0.5	21
51	RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale. <i>Lipids in Health and Disease</i> , 2013, 12, 142.	1.2	4
52	Stimulatory Effects of Cardiotrophin 1 on Atherosclerosis. <i>Hypertension</i> , 2013, 62, 942-950.	1.3	34
53	Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: A long-term follow-up study. <i>Endocrine Journal</i> , 2013, 60, 715-724.	0.7	7
54	Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice. <i>PLoS ONE</i> , 2013, 8, e70933.	1.1	65

#	ARTICLE	IF	CITATIONS
55	Endogenous Bioactive Peptides as Potential Biomarkers for Atherosclerotic Coronary Heart Disease. <i>Sensors</i> , 2012, 12, 4974-4985.	2.1	23
56	High-density lipoprotein subspecies between patients with type 1 diabetes and type 2 diabetes without / with intensive insulin therapy. <i>Endocrine Journal</i> , 2012, 59, 561-569.	0.7	14
57	Associations between Small Dense LDL, HDL Subfractions (HDL2, HDL3) and Risk of Atherosclerosis in Japanese-Americans. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 444-452.	0.9	59
58	Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 974-977.	1.5	58
59	Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice. <i>PLoS ONE</i> , 2012, 7, e35683.	1.1	65
60	Development of a Homogeneous Assay for Measurement of Small Dense LDL Cholesterol. <i>Clinical Chemistry</i> , 2011, 57, 57-65.	1.5	136
61	Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: Associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size. <i>Nephrology</i> , 2011, 16, 558-566.	0.7	7
62	Chronic infusion of salusin- β and - γ exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. <i>Atherosclerosis</i> , 2010, 212, 70-77.	0.4	56
63	Preventive Effects of Heregulin-1 on Macrophage Foam Cell Formation and Atherosclerosis. <i>Circulation Research</i> , 2009, 105, 500-510.	2.0	61
64	Small dense LDL-cholesterol determined by a simple precipitation assay for screening familial combined hyperlipidemia. <i>Atherosclerosis</i> , 2009, 205, 603-607.	0.4	10
65	Serum concentration of small dense low-density lipoprotein-cholesterol during oral glucose tolerance test and oral fat tolerance test. <i>Clinica Chimica Acta</i> , 2008, 387, 36-41.	0.5	11
66	Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. <i>Atherosclerosis</i> , 2008, 197, 154-158.	0.4	44
67	Serum Salusin-ALPHA. Levels Are Decreased and Correlated Negatively with Carotid Atherosclerosis in Essential Hypertensive Patients. <i>Hypertension Research</i> , 2008, 31, 463-468.	1.5	56
68	A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay. <i>Journal of Lipid Research</i> , 2008, 49, 1130-1136.	2.0	48
69	Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. <i>Clinical Science</i> , 2008, 115, 327-334.	1.8	31
70	Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. <i>Journal of Hypertension</i> , 2008, 26, 1955-1965.	0.3	27
71	Small LDL-Cholesterol is Superior to LDL-Cholesterol for Determining Severe Coronary Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 250-260.	0.9	80
72	Effects of Statin on Small Dense Low-Density Lipoprotein Cholesterol and Remnant-Like Particle Cholesterol in Heterozygous Familial Hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 146-153.	0.9	29

#	ARTICLE	IF	CITATIONS
73	Significance of Small Dense Low-Density Lipoproteins in Coronary Heart Disease. , 2008, , 115-123.		0
74	Circadian rhythm of serum concentration of small dense low-density lipoprotein cholesterol. Clinica Chimica Acta, 2007, 376, 96-100.	0.5	12
75	Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease. Metabolism: Clinical and Experimental, 2007, 56, 462-463.	1.5	10
76	Decreased peroxisome proliferator-activated receptor β gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism: Clinical and Experimental, 2007, 56, 1714-1718.	1.5	26
77	The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes. Journal of Atherosclerosis and Thrombosis, 2007, 14, 128-132.	0.9	56
78	Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis, 2006, 189, 206-214.	0.4	102
79	Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabolism: Clinical and Experimental, 2006, 55, 879-884.	1.5	29
80	Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. Journal of Hypertension, 2006, 24, 103-108.	0.3	16
81	Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. Journal of Hypertension, 2005, 23, 1525-1530.	0.3	17
82	Measurement of Small Dense Low-density Lipoprotein Particles. Journal of Atherosclerosis and Thrombosis, 2005, 12, 67-72.	0.9	119
83	Human Urotensin II Accelerates Foam Cell Formation in Human Monocyte-Derived Macrophages. Hypertension, 2005, 46, 738-744.	1.3	100
84	Olmesartan Medoxomil, an Angiotensin II Receptor Blocker Ameliorates Insulin Resistance and Decreases Triglyceride Production in Fructose-Fed Rats. Hypertension Research, 2004, 27, 293-299.	1.5	58
85	Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 558-563.	1.1	113
86	Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E227-E232.	1.8	54
87	Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E955-E961.	1.8	39
88	Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: comparison with postheparin plasma. Metabolism: Clinical and Experimental, 2004, 53, 526-531.	1.5	32
89	Association Between Small Dense Low-Density Lipoprotein and Postprandial Accumulation of Triglyceride-Rich Remnant-Like Particles in Normotriglyceridemic Patients With Myocardial Infarction. Circulation Journal, 2004, 68, 1165-1172.	0.7	17
90	Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: Comparison with apoprotein CIII. Kidney International, 2003, 63, 2171-2177.	2.6	52

#	ARTICLE	IF	CITATIONS
91	Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR- β . <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 22-27.	1.0	56
92	A novel and simple method for quantification of small, dense LDL. <i>Journal of Lipid Research</i> , 2003, 44, 2193-2201.	2.0	171
93	Treatment of Small Dense LDL. <i>Journal of Atherosclerosis and Thrombosis</i> , 2002, 9, 266-275.	0.9	28
94	Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. <i>Atherosclerosis</i> , 2002, 160, 249-256.	0.4	67
95	Effect of simvastatin on apoprotein B ω 3-containing lipoproteins in patients with diabetic nephropathy. <i>Current Therapeutic Research</i> , 2002, 63, 33-42.	0.5	0
96	Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. <i>American Heart Journal</i> , 2002, 144, 1026-1035.	1.2	67
97	No evidence of accelerated atherosclerosis in a 66-yr-old chylomicronemia patient homozygous for the nonsense mutation (Tyr61 \rightarrow Stop) in the lipoprotein lipase gene. <i>Atherosclerosis</i> , 2001, 159, 375-379.	0.4	31
98	Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. <i>American Journal of Hypertension</i> , 2001, 14, 908-913.	1.0	31
99	Small Dense Low-Density Lipoprotein in Japanese Men with Coronary Artery Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 762.	2.0	38
100	Reactions of direct LDL-cholesterol assays with pure LDL fraction and IDL: comparison of three homogeneous methods. <i>Clinica Chimica Acta</i> , 2000, 295, 97-106.	0.5	50
101	Vascular endothelial markers, von willebrand factor and thrombomodulin index, are specifically elevated in type 2 diabetic patients with nephropathy: comparison of primary renal disease. <i>Clinica Chimica Acta</i> , 2000, 299, 65-75.	0.5	29
102	Long-term efficacy of bezafibrate in reduction of small, dense low-density lipoprotein by hypotriglyceridemic action. <i>Current Therapeutic Research</i> , 2000, 61, 127-136.	0.5	12
103	Lipoprotein abnormalities in diabetic nephropathy. <i>Kidney International</i> , 1999, 56, S22-S24.	2.6	47
104	Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. <i>Kidney International</i> , 1999, 56, S227-S228.	2.6	43
105	High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia. <i>Atherosclerosis</i> , 1998, 141, 77-85.	0.4	48
106	Dyslipidemia in diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 1996, 33, 1-14.	1.1	48
107	High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. <i>Atherosclerosis</i> , 1996, 123, 57-72.	0.4	38
108	Intracellular apoprotein B degradation is suppressed by decreased albumin concentration in Hep G2 cells. <i>Kidney International</i> , 1995, 47, 421-431.	2.6	16

#	ARTICLE	IF	CITATIONS
109	The effect of exogenous arachidonic acid on insulin secretion in isolated perfused hamster islets.. Endocrinologia Japonica, 1984, 31, 549-555.	0.5	4